Investor Presentaiton
North America
Competitive pressures witnessed in specific products
US quarterly sales (US$ Mn)
Q1FY22
35%)
YOY
QoQ
9.6%
10.8%
LUPIN
Consolidating our position in the US¹
#3
#3
#3
#3
#4
#4
180
188
195
172
157
29.4% average
market share²
#5
129
123
121
120
109
79
83
65
65
51
63
53
44
45
55
55
Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22
US Generics: Established Leader
3rd
Largest in the
US
(by prescriptions¹)
Note:
1. IQVIA Jun-21; ^AG - Authorized generic
149
Filings pending
approval
(cumulative)
202
DMF filings
(cumulative)
2015-16 2016-17 2017-18
No. of Products (mkt leader)
2018-19
2019-20 2020-21
Q1 FY22
Top 3 by mkt share US Rx pharma ranking
• Focus on maximizing inhalation generic opportunities -
Albuterol and Brovana AG^
• Successfully completed launch of Trichomoniasis indication
for Solosec; 1st and only single-dose oral prescription
antimicrobial agent for the treatment of both trichomoniasis
and bacterial vaginosis approved by the U.S.FDA
• 50 FTF's incl. 18 exclusive FTF await U.S.FDA approval
07View entire presentation